Propeller Health
https://www.propellerhealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Propeller Health
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Novartis Triple Combo Enerzair Gets EU OK For Asthma
The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.
ResMed Ready To Supply Digital Answers To Health Care’s Demand Challenges
ResMed’s respiratory device portfolio has put it front and center of the global medtech industry’s efforts to bring COVID-19 under control. UK and Ireland country manager Antoine Valterio tells In Vivo how the company rose to the challenge, and how providers are now seeing digital technologies in a new light.
Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
Company Information
- Other Names / Subsidiaries
-
- Asthmapolis
- Reciprocal Labs Corporation